No registrations found.
ID
Source
Brief title
Health condition
COVID-19, SARS-CoV-2
Sponsors and support
Intervention
Outcome measures
Primary outcome
To estimate secondary attack rates of SARS-CoV-2 and determine factors that impact susceptibility and infectiousness.
Secondary outcome
To determine the clinical presentation of COVID-19.
To determine the proportion of symptomatic and asymptomatic SARS-CoV-2 infections within households.
To determine the dynamics and the anatomical sites of virus replication in COVID-19 cases.
To determine immunological dynamics in COVID-19 cases.
To assess the serological and cellular immune response of COVID-19 cases.
Background summary
In December 2019 the first infections of SARS-CoV-2 (COVID-19 disease) were detected in Wuhan, China. The first COVID-19 case in the Netherlands was confirmed on February 27, 2020. In March 2020, the Dutch government mandated a partial lockdown, characterized by social distancing, self-quarantine, closing of schools, bars, and restaurants, and urging people to work from home. As household members live in close contact, the household constitutes a high risk setting for SARS-CoV-2 transmission. The main aims of the present study were to determine the important clinical, epidemiological, virological and immunological characteristics of first COVID-19 cases in the Netherlands and their household contacts. We wanted to estimate secondary attack rates of SARS-CoV-2 and to determine factors that impact susceptibility and infectiousness, stratified by the age of household contacts. We used a dense sampling strategy with sampling from various anatomical sites and by using several molecular and serological diagnostics methods to determine the presence of the SARS-CoV-2 virus.
Study objective
Secondary attack rates of SARS-CoV-2 will differ when stratified for the age of the index case.
Study design
T1: Home visit within 24 hours after positive test of index case. At this time point we collect questionnaire, serum, naso- and oropharyngeal swabs, saliva and feces.
T2: Home visit 2-3 weeks after inclusion. Data that are collected include questionnaire, serum, swabs, saliva and feces.
T3: Home visit 4-6 weeks after inclusion. Collection of questionnaire, serum, saliva and feces.
T4: Self sampling 6 months after inclusion. Serum by self-sampling (finger prick) and questionnaire.
T5: home visit 9-10 months after inclusion. To collect questionnaire, serum and saliva samples.
Intervention
Not applicable
Inge Roof
+31629649396
inge.roof@rivm.nl
Inge Roof
+31629649396
inge.roof@rivm.nl
Inclusion criteria
Any person 16 years and older testing positive for SARS-CoV-2 (index case) who had at least one child in their household below the age of 18 and consented to be contacted for scientific research. Every household contact (persons living in the same house as the index patient) was to be enrolled in the study.
Exclusion criteria
Household contacts below the age of 1. Households were excluded if one or more of the household contacts did not want to participate in the study upfront.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL9850 |
| CCMO | NL13529.041.06 |
| OMON | NL-OMON54806 |